# Alpha Lipoic Acid Blood Glucose Meta-analysis: What the Evidence Says Canonical: https://www.migaku.app/guides/alpha-lipoic-acid-blood-glucose-meta-analysis-evidence-review Category: evidence-review Summary: Alpha Lipoic Acid Blood Glucose Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa Last reviewed: 2026-05-22 Reviewed by: Migaku Evidence Review # Alpha Lipoic Acid Blood Glucose Meta-analysis: What the Evidence Says ## Quick Answer Alpha Lipoic Acid Blood Glucose Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice. ## Key Takeaways - This page is generated only from sources stored in the Migaku evidence knowledge base. - Current evidence mix: 2 preclinical study. - Claims should be interpreted with the source type, study design, population, and publication date in mind. - This article is educational and does not replace care from a qualified clinician. ## Evidence Map | Source | Evidence type | Level | Date | Identifier | | --- | --- | ---: | --- | --- | | Alpha‐Lipoic Acid Reduces NLRP3 / ASC Expression and IL ‐1β Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium | preclinical study | 4 | 2026-02-03 | 10.1002/fsn3.71517 | | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study | preclinical study | 4 | 2025-11-13 | 10.2147/DMSO.S548285 | ## What The Sources Report - T2DM is primarily characterized by insulin resistance, a pathological condition in which target tissues exhibit a reduced response to insulin, a hormone essential for glucose regulation and uptake (Ahmad et al. ). [Ko Chih‐Yuan (2026); evidence level 4] - A growing body of evidence supports the notion that oxidative stress and chronic low-grade inflammation are fundamental contributors to the pathogenesis of insulin resistance (Juzbašić et al. ; Rains and Jain ). [Ko Chih‐Yuan (2026); evidence level 4] - During the study period, 3 patients in the roflumilast group dropped out secondary to non-adherence (n=2) and the development of thyroid cancer (n=1), and 3 patients in the alpha-lipoic acid group also dropped out as a result of non-compliance. [Elsharab Asmaa (2025); evidence level 4] - Roflumilast treatment reduced FBG from 140 (17) to 118 (11) (P1<0.001), while alpha-lipoic acid reduced FBG from 139 (12) to 123 (10) (P1<0.001). [Elsharab Asmaa (2025); evidence level 4] ## How To Read This Evidence Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade. ## Practical Interpretation For alpha lipoic acid blood glucose meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources. ## Limits Of This First Pass This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review. ## References - Ko Chih‐Yuan (2026). Alpha‐Lipoic Acid Reduces NLRP3 / ASC Expression and IL ‐1β Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium. DOI: 10.1002/fsn3.71517. PMCID: PMC12868922. PMID: 41648644. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12868922/ - Elsharab Asmaa (2025). Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. DOI: 10.2147/DMSO.S548285. PMCID: PMC12621582. PMID: 41256904. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12621582/ ## Safety Note Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.